We would love to hear your thoughts about our site and services, please take our survey here.
"Another peer review, fantastic, the fridge door will look busy with all the peer reviews - can't do anything with them but they do look good." such a foolishly unnecessary comment. I appreciate it's not the development that we're all looking for but you can't really do a great deal without them... so a step in the right direction
alwayslocked - Firstly don't be a ****. This is exactly the purpose of BB for people to share ideas and if they feel like it, to celebrate successes with eachother either virtually or physically.
Secondly - you clearly know nothing about the pharma industry. Astra has just bid 39bn for a rare disease company that generates nowhere near enough cashflow to substantiate such a multiple based on blunt valuation metrics only. Unless you work in pharma M&A, or can substantiate that claim, kindly don't be so arrogant in your dismissal of it.
Eva can you elaborate on your specific concern about lack of IND for P3?
My understanding is the same IND is applied across all clinical trial phases and is adapted as required / in conversation with the FDA. Are you referring to a lick of update? If so, could this not also be due to conversations around accelerated review or usage prior to approval?
Thanks!
@Scinv agree with most of your comment but regarding the manufacturing issue you mention, RM has said on a number of occasions that the previous £14m raising would be used to fund a ramp up of production of the drug. I would expect therefore, that there exists a significant volume ready to go and future orders will be used to increase production as required. I don't see manufacturing as a core issue influencing the SP, but I do agree that publishing the full dataset is becoming a bit of a concern
Good article - thanks for posting. Pity no mention of Synairgen tbh but hopefully increased general awareness of the potential benefits of Interferon will take us a step closer to everyone knowing the name Synairgen :) GLA
I'm not aware of any news on how home trial recruitment is progressing. I think there is some confusion on this due to the conflation of the hospital trial and home trial communications (https://www.synairgen.com/wp-content/uploads/2020/05/200528-Synairgen-Completion-of-Recruitment.pdf).
My understanding is hospital trial recruitment = complete and results due July. Home trial recruitment = ongoing and no news on progress.
I'm hoping to see a return to nearer 60 today. The recruitment completion RNS removes a lot of concern about whether Synairgen can bring this trial home which should in turn lead to a focus on the science which (I don't think many of us on here are in any doubt) looks positive! GLA
I would argue that we haven't seen any "good news", what we've seen is an increase in news coverage.. but the market is interpreting that news cautiously as you would expect. It is rarely a good sign when you see a pivot away from the initial protocol... particularly when you have to question the cash flow of the company funding an additional / extension trial.
That being said I'm in and holding for results - keeping my fingers crossed for definitively good news which would undoubtedly see this share rocket